These data indicated that both sorafenib and BBOX1-AS1 knockdown could inhibit the growth of HCC organoids, while a combination of BBOX1-AS1 knockdown with sorafenib had a stronger killing effect than sorafenib alone (Figures 8D and 8E). The gene discussed is BBOX1; the disease is hepatocellular carcinoma.